U.S. spending on GLP-1 receptor agonists reached $71.7 billion in 2023. Semaglutide and tirzepatide products have captured 70% of the market as diabetes and weight loss medication use rapidly expands, according to new research.
March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
Here, I discuss the primary reasons for patient nonadherence and how, specifically, allied staff can play a role in increasing the likelihood of patients adhering to their follow-up visits and prescribed treatment plans for their ocular conditions.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
At 12 months, women on hormone therapy achieved 16% total body weight loss with semaglutide, compared to 12% in those not using hormone therapy, researchers reported.